Modern MES solution is an advanced and lighter version of MES. It helps enhance pharmaceutical industry production processes without requiring custom coding. The digital production records and automated workflows that foster right-first-time batches provided by the modern MES will further help increase efficiency. In addition, the fast and flexible responsiveness of the modern MES solution will make it easier to change production lines and accommodate small batches. The solution provides real-time visibility by helping retrieve data from local and remote locations. Thus, various pharma companies are shifting to modern MES solutions to develop high-quality pharmaceutical products and enhance production performance. Some examples of modern MES solutions are Tulip’s Next Gen MES, MasterControl’s MES, 42Q’s MES 101, and EIS’s OpsTrakker Solution Suite, among others. Bristol-Myers Squibb, Synthego Corporation, Sri Krishna Pharmaceuticals Limited, EpiBone, and Fagron NV are among the users of these modern MES solutions. Such factors are expected to promote the adoption of modern manufacturing execution systems among life sciences players during the forecast period.
Middle East, Saudi Arabia is the largest pharmaceutical manufacturing market, which accounts for 60% of the regional share, followed by the UAE. The largest part of the Saudi manufacturing industry is spread in the Gulf region, however, most of the local production is destined for export markets. Leading indigenous players in the region include Spimaco, Jamjoom Pharma, Tabuk Pharmaceutical Manufacturing, Jazeera Pharmaceutical Industries, and Julphar. Top multinational companies such as GSK, Sanofi, and Abbott Laboratories have also set up manufacturing units in the region. Per the Saudi Vision 2030, the country is a unique transformative economic and social reform blueprint. With this vision, it is opening up to the world and looking for the upgrading of its healthcare sector. The progressive healthcare and life sciences sector would bring huge growth avenues to the MES in life sciences market during the forecast period.
The Middle East & Africa manufacturing execution system in life sciences market is segmented into offering, deployment, organization size, application, and country.
Based on offering, the Middle East & Africa manufacturing execution system in life sciences market is segmented into software and services. The services segment held a larger share of the Middle East & Africa manufacturing execution system in life sciences market in 2023.
Based on deployment, the Middle East & Africa manufacturing execution system in life sciences market is segmented into on-premises and cloud. The cloud segment held a larger share of the Middle East & Africa manufacturing execution system in life sciences market in 2023.
Based on organization size, the Middle East & Africa manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held the largest share of the Middle East & Africa manufacturing execution system in life sciences market in 2023.
Based on application, the Middle East & Africa manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The medical devices segment held the largest share of the Middle East & Africa manufacturing execution system in life sciences market in 2023.
Based on country, the Middle East & Africa manufacturing execution system in life sciences market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. The UAE dominated the share of the Middle East & Africa manufacturing execution system in life sciences market in 2023.
ATS Global B.V.; Emerson Electric Co; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG are the leading companies operating in the Middle East & Africa manufacturing execution system in life sciences market.